secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001356576-24-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus to present interim Phase IIa data for SPN-817 on May 23
----------------------------------------------------------------

- Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.
- Webcast at 4:30 p.m. ET; replay and slides available for 60 days via company website.
- No actual clinical results disclosed in this filing; full data release scheduled for the event.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/0001356576-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/supn-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer